- California's stem cell agency, California Institute for Regenerative Medicine, awards ImmunoCellular Therapeutics (OTCPK:IMUC +19.5%) $19.9M to support the Phase 3 clinical trial of ICT-107 in patients with newly diagnosed glioblastoma. The funds were granted under the Institute's CIRM 2.0 program, a comprehensive collaborative initiative designed to accelerate the development of stem cell-based treatments for people with unmet medical needs. ICT-107 qualified for consideration on the basis of being specifically engineered as an immunotherapy that selectively targets and kills tumor stem cells with the goal of preventing tumor recurrence following standard-of-care treatment.
- The funds will be dispersed over the duration of the study, expected to commence in Q4. The estimated final data collection for the primary endpoint (overall survival at 46 months vs. placebo) is December 2019. The estimated study completion date is December 2021.
-
ICT-107 is an autologous dendritic cell immunotherapeutic that targets six different antigens associated with glioblastoma, the most common and lethal form of brain cancer. It is designed for use following surgical tumor resection of newly diagnosed glioblastoma in combination with radiotherapy and chemotherapy.